A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07549646 |
24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07110246 |
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas |
RECRUITING | PHASE2 |
| NCT06475989 |
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
RECRUITING | PHASE3 |
| NCT04940052 |
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04116541 |
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. |
RECRUITING | PHASE2 |
| NCT03975829 |
Pediatric Long-Term Follow-up and Rollover Study |
RECRUITING | PHASE4 |
| NCT03825289 |
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer |
TERMINATED | PHASE1 |
| NCT03784014 |
Molecular Profiling of Advanced Soft-tissue Sarcomas |
COMPLETED | PHASE3 |
| NCT03363217 |
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03149029 |
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
